Blueprint Medicines to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
Blueprint Medicines (NASDAQ: BPMC) has announced it will host a live conference call and webcast to report its fourth quarter and full year 2024 financial results on Thursday, February 13, 2025, at 8:00 a.m. ET. The company will also provide a corporate update during the event.
Investors can access the conference call by dialing 833-470-1428 (domestic) or 404-975-4839 (international) with conference ID 349846. A webcast will be available on the company's investor relations website, with an archived version accessible for 30 days after the call.
Blueprint Medicines (NASDAQ: BPMC) ha annunciato che organizzerà una conferenza telefonica dal vivo e una trasmissione in webcast per riportare i suoi risultati finanziari del quarto trimestre e dell'intero anno 2024 giovedì 13 febbraio 2025, alle 8:00 ET. L'azienda fornirà inoltre un aggiornamento aziendale durante l'evento.
Gli investitori possono accedere alla conferenza telefonica componendo il numero 833-470-1428 (nazionale) o 404-975-4839 (internazionale) con l'ID conferenza 349846. Una trasmissione in webcast sarà disponibile sul sito web delle relazioni con gli investitori dell'azienda, con una versione archiviata accessibile per 30 giorni dopo la chiamata.
Blueprint Medicines (NASDAQ: BPMC) ha anunciado que llevará a cabo una conferencia telefónica en vivo y una transmisión por webcast para informar sobre sus resultados financieros del cuarto trimestre y del año completo 2024 el jueves 13 de febrero de 2025, a las 8:00 a.m. ET. La empresa también proporcionará una actualización corporativa durante el evento.
Los inversores pueden acceder a la conferencia telefónica marcando el 833-470-1428 (doméstico) o el 404-975-4839 (internacional) con el ID de conferencia 349846. Una transmisión por webcast estará disponible en el sitio web de relaciones con inversionistas de la empresa, con una versión archivada accesible durante 30 días después de la llamada.
Blueprint Medicines (NASDAQ: BPMC)는 2024년 4분기 및 전체 연도 재무 결과에 대한 발표를 위해 2025년 2월 13일 목요일 오전 8시 ET에 라이브 컨퍼런스 콜 및 웹캐스트를 개최한다고 발표했습니다. 행사 동안 회사는 또한 기업 업데이트를 제공할 예정입니다.
투자자들은 833-470-1428(국내) 또는 404-975-4839(국제)로 전화해 회의 ID 349846로 컨퍼런스 콜에 접속할 수 있습니다. 회사의 투자자 관계 웹사이트에서 웹캐스트를 확인할 수 있으며, 통화 후 30일 동안 아카이브된 버전이 제공됩니다.
Blueprint Medicines (NASDAQ: BPMC) a annoncé qu'elle organisera une conférence téléphonique en direct et un webcast pour présenter ses résultats financiers du quatrième trimestre et de l'année entière 2024, le jeudi 13 février 2025, à 8h00 ET. L'entreprise fournira également une mise à jour corporative lors de l'événement.
Les investisseurs peuvent accéder à la conférence téléphonique en composant le 833-470-1428 (national) ou le 404-975-4839 (international) avec l'ID de conférence 349846. Un webcast sera disponible sur le site Web des relations investisseurs de l'entreprise, avec une version archivée accessible pendant 30 jours après l'appel.
Blueprint Medicines (NASDAQ: BPMC) hat angekündigt, dass es eine Live-Konferenzschaltung und ein Webcast veranstaltet, um über seine Finanzergebnisse für das vierte Quartal und das gesamte Jahr 2024 zu berichten, und zwar am Donnerstag, den 13. Februar 2025, um 8:00 Uhr ET. Das Unternehmen wird während der Veranstaltung auch ein Unternehmensupdate geben.
Anleger können auf die Konferenzschaltung zugreifen, indem sie die Nummer 833-470-1428 (inländisch) oder 404-975-4839 (international) mit der Konferenz-ID 349846 wählen. Ein Webcast wird auf der Investor-Relations-Website des Unternehmens verfügbar sein, wobei eine archivierte Version 30 Tage nach dem Anruf zugänglich sein wird.
- None.
- None.
To access the live conference call, please dial 833-470-1428 (domestic) or 404-975-4839 (international) and refer to conference ID 349846. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is a global, fully integrated biopharmaceutical company that invents life-changing medicines. We seek to alleviate human suffering by solving important medical problems in two core focus areas: allergy/inflammation and oncology/hematology. Our approach begins by targeting the root causes of disease, using deep scientific knowledge in our core focus areas and drug discovery expertise across multiple therapeutic modalities. We have a track record of success with two approved medicines, including AYVAKIT®/AYVAKYT® (avapritinib) which we are bringing to patients with systemic mastocytosis (SM) in the
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-fourth-quarter-and-full-year-2024-financial-results-on-thursday-february-13-2025-302368185.html
SOURCE Blueprint Medicines Corporation
FAQ
When will Blueprint Medicines (BPMC) report Q4 and full year 2024 earnings?
How can investors access BPMC's Q4 2024 earnings call?
How long will BPMC's Q4 2024 earnings webcast be available?
What will be discussed in BPMC's February 13, 2025 conference call?
